Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF LONG-TERM SAFETY CLINICAL TRIAL OF KX-826 TINCTURE 1.0% FOR THE TREATMENT OF MALE ADULT AGA IN CHINA

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest developments related to the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the long-term safety clinical trial (the "**Long-term Safety Clinical Trial**") of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of androgenetic alopecia ("**AGA**") has completed follow-up visits for the subjects, demonstrating favorable safety.

In accordance with the ICH-E1 guidance principle and the requirements of the National Medical Products Administration of the PRC (the "**NMPA**") Announcement (No. 88 of 2019) on the Application of "E1: The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life Threatening Conditions", KX-826 tincture 1.0%, as a drug intended for the long-term treatment of non-life-threatening conditions (chronic or intermittent use for more than 6 months), is required to undergo a 1-year long-term trial to assess its safety. To meet the above-mentioned requirements, the Long-term Safety Clinical Trial adopted a multi-center, open-label design and aims to evaluate the long-term safety of the topical use of KX-826 tincture 1.0% for the treatment of AGA patients in China (treatment period of 1 year).

The Long-term Safety Clinical Trial involves a total of 12 clinical research centers in China, with Professor Jianzhong Zhang (張建中) and Professor Cheng Zhou (周城) from Peking University People's Hospital serving as the lead principal investigators. The primary endpoint of the trial is the incidence of treatment-emergent adverse events ("**TEAE**") that occurred during the study and other safety indicators. This trial adopted KX-826 tincture 1.0% BID (i.e. twice a day) as the drug-related dosage. The results of the clinical trial exhibited satisfactory safety.

As an essential trial for the submission of the new drug application (NDA) for KX-826, the results of the Long-term Safety Clinical Trial further validate the safety and efficacy of long-term use of KX-826. These results, together with other materials including the positive phase III clinical trial results announced in March 2026, will be incorporated into the main NDA submission package and submitted to the NMPA in the near future.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: Apart from the cosmetic products of 826 topical anti-hair loss solution and acne cream, there is no assurance that other products of KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 3 November 2026

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Yunfei Chen and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purposes only*